C2T-admin

/C2T-admin

About C2T-admin

This author has not yet filled in any details.
So far C2T-admin has created 14 blog entries.

C2 Therapeutics Announces 15th Patient Enrollment in its Clinical Trial

2018-05-30T19:48:05+00:00

C2 Therapeutics, a privately held company founded to address the limitations of current Barrett’s Esophagus (BE) treatment options, today announced that it enrolled the 15th patient in its Cryoballoon Focal Ablation System international study. Additionally, 10 patients have reached the 2-month follow-up period.

Click here for full release.

C2 Therapeutics Announces 15th Patient Enrollment in its Clinical Trial 2018-05-30T19:48:05+00:00

DDW2012

2018-05-30T19:48:06+00:00

Initial Human Experience with a Novel Through-the-scope Cryoballoon Device for Mucosal Ablation

The abstract, Initial Human Experience with a Novel Through-the-scope Cryoballoon Device for Mucosal Ablation (1299398) will be presented during the 53rd Annual Meeting of The Society for Surgery of the Ailmentary Tract (SSAT) in conjunction with DDW at the San Diego Convention Center in San Diego, California.

The abstract can be viewed here: http://meetings.ssat.com/abstracts/2012/QS17.cgi

DDW2012 2018-05-30T19:48:06+00:00

Start-up Uses Freezing Balloon to Treat Pre-Cancerous Esophagus

2018-05-30T19:48:06+00:00

Redwood City-based C2Therapeutics is hoping to kill diseased tissue in people’s esophaguses before it becomes one of the most deadly cancers of the human body.  For the 40 million Americans with acid reflux disease, treatment is often over the counter medication or a simple change in diet. However, one in five with acid reflux will likely develop Barrett’s Esophagus, a pre-cancerous condition that makes patients 30 to 125 times more likely to develop cancer of the esophagus.  See Complete Story.

Start-up Uses Freezing Balloon to Treat Pre-Cancerous Esophagus 2018-05-30T19:48:06+00:00

Preclinical Testing Complete

2018-05-30T19:48:06+00:00

The CryoBalloon device enables circumferential mucosal ablation in a 1-step process by using a novel, through-the-scope balloon. The maximal effect on the mucosa is achieved with a 12-second application time. Because of its ease of use, this new device merits further study so that we can find its possible role in the treatment of Barrett’s esophagus.

Read the full abstract here.

Preclinical Testing Complete 2018-05-30T19:48:06+00:00